| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
2 companies
Dexcel Pharma Technologies Ltd. is a 10% Owner at Roivant Sciences Ltd. with holdings across 2 companies. Recent SEC Form 4 filings include 3 buys and 2 sells.
Estimated insider holdings value: $3221.9M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2022 | ROIV Roivant Sciences Ltd. | 10% Owner | Buy | 4,000,000 | $5.00 | $20,000,000.00 | +4.0% | +48.5% | +70.1% | |
| Apr 25, 2022 | ROIV Roivant Sciences Ltd. | 10% Owner | Buy | 40,285 | $3.85 | $154,954.16 | - | +2.7% | +115.8% | |
| Jun 3, 2021 | PLX Protalix Biotherapeutics, Inc. | 10% Owner | Sell | 918,717 | $2.27 | $2,088,857.27 | -10.2% | -28.4% | -44.1% |